Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-ranging study of pradefovir in patients with compensated hepatitis B

Trial Profile

Dose-ranging study of pradefovir in patients with compensated hepatitis B

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Pradefovir (Primary) ; Adefovir dipivoxil
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
  • Most Recent Events

    • 03 Jul 2012 Extension study data integrated (NCT00230490).
    • 21 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 26 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top